Adv over Selegeline - OD dose, milder S/E, non-amphetamine metabolites
ADAGIO trial suggested neuroprotective at 1mg, but findings did not hold at 2mg/day.
Concepts/ Anatomical substrates/ Physiology and pathophysiology/ Reading between the lines/ The why and why not/ Looking from another angle/ Molecular basis/ Ideas
Adv over Selegeline - OD dose, milder S/E, non-amphetamine metabolites
ADAGIO trial suggested neuroprotective at 1mg, but findings did not hold at 2mg/day.